Inicio
| Volver a la pantalla de resultados de la última búsqueda | Consultar el historial de búsquedas | Volver a la pantalla de inicio |
Detalle del título uniforme
Anticancer Research
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (3)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Título : Biomarkers of pituitary neoplasms Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis apoptosis p53 p27 cox-2 folliculostellate cells galectin-3 hif-1alpha inflammation and tumor matrix metalloproteinases (MMPS) microarray microenvironment microvessel density (MVD) pituitary stem cells proliferative marker (ki-67) pituitary tumor-transforming gene (PTTG) topoisomerase-2-alpha tumor heterogeneity VEGF review Resumen : In a wide spectrum of tumors, cell proliferation, vascularity, apoptosis, cell adhesion, and cell-cycle progression may indicate tumor progression. In this review article, the literature regarding apoptotic markers and p53, as well as cyclooxygenase-2, galectin-3, and pituitary tumor transforming factor, proliferative markers, angiogenesis, including vascular endothelial growth factor and its receptor, pituitary tumor-transforming gene, microarrays, stem cells, and microenvironment and tumor heterogeneity are presented. Only a particular group of selected biomarkers show promise in differentiating pituitary tumors which will behave in an aggressive manner. Therefore, the most common and promising biomarkers and terms were analyzed, proposing the need for uniform design and application of methods and standardized criteria for the interpretation of results. The new spectrum of biomarkers may shed light upon the pathogenetic mechanisms and also may serve as standardized diagnostic tool for daily pathologic practice. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V. Syro, Bernd W. Scheithauer, and Kalman Kovacs Referencia : Anticancer Res. 2012; 32:(11)4639-54. En línea : http://ar.iiarjournals.org/content/32/11/4639.abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3635 Biomarkers of pituitary neoplasms [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Anticancer Research
Idioma : Inglés (eng)
Palabras clave : Angiogenesis apoptosis p53 p27 cox-2 folliculostellate cells galectin-3 hif-1alpha inflammation and tumor matrix metalloproteinases (MMPS) microarray microenvironment microvessel density (MVD) pituitary stem cells proliferative marker (ki-67) pituitary tumor-transforming gene (PTTG) topoisomerase-2-alpha tumor heterogeneity VEGF review Resumen : In a wide spectrum of tumors, cell proliferation, vascularity, apoptosis, cell adhesion, and cell-cycle progression may indicate tumor progression. In this review article, the literature regarding apoptotic markers and p53, as well as cyclooxygenase-2, galectin-3, and pituitary tumor transforming factor, proliferative markers, angiogenesis, including vascular endothelial growth factor and its receptor, pituitary tumor-transforming gene, microarrays, stem cells, and microenvironment and tumor heterogeneity are presented. Only a particular group of selected biomarkers show promise in differentiating pituitary tumors which will behave in an aggressive manner. Therefore, the most common and promising biomarkers and terms were analyzed, proposing the need for uniform design and application of methods and standardized criteria for the interpretation of results. The new spectrum of biomarkers may shed light upon the pathogenetic mechanisms and also may serve as standardized diagnostic tool for daily pathologic practice. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V. Syro, Bernd W. Scheithauer, and Kalman Kovacs Referencia : Anticancer Res. 2012; 32:(11)4639-54. En línea : http://ar.iiarjournals.org/content/32/11/4639.abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3635 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000206 AC-2012-046 Archivo digital Producción Científica Artículos científicos Disponible Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy / Luis Vicente Syro Moreno
Título : Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Palabras clave : Angiogenesis cancer CD105 endoglin tumor review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555 Endoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy [documento electrónico] / Luis Vicente Syro Moreno, . - 2011.
Obra : Anticancer Research
Idioma : Inglés (eng)
Palabras clave : Angiogenesis cancer CD105 endoglin tumor review Resumen : Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd Referencia : Anticancer Res. 2011 Jun;31(6):2283-90. PMID : 21737653 En línea : http://ar.iiarjournals.org/content/31/6/2283.full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3555 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000124 AC-2011-009 Archivo digital Producción Científica Artículos científicos Disponible
Título : Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2009 Títulos uniformes : Anticancer Research Idioma : Inglés (eng) Resumen : O6-Methylguanine-DNA-methyltransferase (MGMT) is a unique protein, which both repairs O6-alkylguanine lesions stoichiometrically without a multi-enzymatic pathway and self-inactivates. It has recently been linked to the therapeutic success of alkylating agent chemotherapy, specifically temozolomide treatment. This drug affects the MGMT pathway to induce cell death in tumor tissue. Low levels of functional MGMT have been correlated with success of treatment, while high levels bring about failure of therapy. Expression of MGMT protein varies in normal and tumoral tissue. Furthermore, its epigenetic silencing due to promoter methylation has been linked to its lack of expression in many types of tumor, including gliomas. Great enthusiasm surrounds the utility of this protein in cancer treatment. Not only has there been success in manipulating MGMT levels to enhance alkylating agent therapy, but studies also suggest a possible role of MGMT in protecting hematopoietic cells from the myelosuppressive effects of high-dose chemotherapy. Innovative research into this protein will no doubt be rewarding. This review presents a summary of what is known about this unique protein, including its structure, function in its pathway, polymorphisms, expression in normal and tumoral tissue, relation to alkylating agent therapy, and possible future applications. Mención de responsabilidad : Soniya Sharma, Fateme Salehi, Bernd W Scheithauer, Fabio Rotondo, Luis V Syro, Kalman Kovacs Referencia : Anticancer Res. 2009 Oct;29(10):3759-68. PMID : 19846906 En línea : http://ar.iiarjournals.org/content/29/10/3759.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4451 Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis [documento electrónico] / Luis Vicente Syro Moreno, . - 2009.
Obra : Anticancer Research
Idioma : Inglés (eng)
Resumen : O6-Methylguanine-DNA-methyltransferase (MGMT) is a unique protein, which both repairs O6-alkylguanine lesions stoichiometrically without a multi-enzymatic pathway and self-inactivates. It has recently been linked to the therapeutic success of alkylating agent chemotherapy, specifically temozolomide treatment. This drug affects the MGMT pathway to induce cell death in tumor tissue. Low levels of functional MGMT have been correlated with success of treatment, while high levels bring about failure of therapy. Expression of MGMT protein varies in normal and tumoral tissue. Furthermore, its epigenetic silencing due to promoter methylation has been linked to its lack of expression in many types of tumor, including gliomas. Great enthusiasm surrounds the utility of this protein in cancer treatment. Not only has there been success in manipulating MGMT levels to enhance alkylating agent therapy, but studies also suggest a possible role of MGMT in protecting hematopoietic cells from the myelosuppressive effects of high-dose chemotherapy. Innovative research into this protein will no doubt be rewarding. This review presents a summary of what is known about this unique protein, including its structure, function in its pathway, polymorphisms, expression in normal and tumoral tissue, relation to alkylating agent therapy, and possible future applications. Mención de responsabilidad : Soniya Sharma, Fateme Salehi, Bernd W Scheithauer, Fabio Rotondo, Luis V Syro, Kalman Kovacs Referencia : Anticancer Res. 2009 Oct;29(10):3759-68. PMID : 19846906 En línea : http://ar.iiarjournals.org/content/29/10/3759.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4451 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000951 AC-2009-039 Archivo digital Producción Científica Artículos científicos Disponible
